Ibrutinib inhibits Bruton’s tyrosine kinase, which is highly expressed in B cell malignancies; this inhibitor increases anti-tumor activity in synergism with CD19 CAR-T cells, simultaneously lowering the severity of CRS in patients with CLL [273]. This evidence concerns the gene CD19 and congenital rubella syndrome.